
Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia) and NCHS public use data file for the total US.

Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

The APC is the Annual Percent Change over the time interval.

* The APC is significantly different from zero (p<.05).
## Trends in SEER Incidence Rates by Primary Cancer Site
### 1992-2002

**Ages Less Than 65**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>APC, 1992-2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver &amp; IBD</td>
<td>4.7*</td>
</tr>
<tr>
<td>Thyroid</td>
<td>4.4*</td>
</tr>
<tr>
<td>Prostate</td>
<td>3.1*</td>
</tr>
<tr>
<td>Kidney &amp; Renal Pelvis</td>
<td>1.7*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>1.4*</td>
</tr>
<tr>
<td>Testis</td>
<td>1.0*</td>
</tr>
<tr>
<td>Corpus &amp; Uterus, NOS</td>
<td>0.6*</td>
</tr>
<tr>
<td>Breast (Female)</td>
<td>0.4</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.3*</td>
</tr>
<tr>
<td>All Except Lung</td>
<td>0.0</td>
</tr>
<tr>
<td>Colon &amp; Rectum</td>
<td>-0.1</td>
</tr>
<tr>
<td>All Cancer Sites</td>
<td>-0.4</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>-0.5*</td>
</tr>
<tr>
<td>Brain &amp; ONS</td>
<td>-0.7*</td>
</tr>
<tr>
<td>Myeloma</td>
<td>-0.8*</td>
</tr>
<tr>
<td>Leukemia</td>
<td>-1.2*</td>
</tr>
<tr>
<td>Ovary</td>
<td>-1.3*</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx</td>
<td>-1.6*</td>
</tr>
<tr>
<td>Esophagus</td>
<td>-2.2*</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>-2.8*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>-3.4*</td>
</tr>
<tr>
<td>Stomach</td>
<td>-3.7*</td>
</tr>
<tr>
<td>Lung &amp; Bronchus (Female)</td>
<td></td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td></td>
</tr>
<tr>
<td>Lung &amp; Bronchus (Male)</td>
<td></td>
</tr>
</tbody>
</table>

**Ages 65 and Over**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>APC, 1992-2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid</td>
<td>3.9*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>3.8*</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>2.4*</td>
</tr>
<tr>
<td>Kidney &amp; Renal Pelvis</td>
<td>1.4*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>1.2*</td>
</tr>
<tr>
<td>Lung &amp; Bronchus (Female)</td>
<td>0.9*</td>
</tr>
<tr>
<td>Esophagus</td>
<td>0.8*</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>0.3</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>0.3</td>
</tr>
<tr>
<td>Breast (Female)</td>
<td>-0.5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>-0.6</td>
</tr>
<tr>
<td>Myeloma</td>
<td>-0.9*</td>
</tr>
<tr>
<td>Brain &amp; ONS</td>
<td>-1.0*</td>
</tr>
<tr>
<td>All Cancer Sites</td>
<td>-1.1*</td>
</tr>
<tr>
<td>All Except Lung</td>
<td>-1.1*</td>
</tr>
<tr>
<td>Testis</td>
<td>-1.2*</td>
</tr>
<tr>
<td>Leukemia</td>
<td>-1.4*</td>
</tr>
<tr>
<td>Ovary</td>
<td>-1.4*</td>
</tr>
<tr>
<td>Colon &amp; Rectum</td>
<td>-1.6*</td>
</tr>
<tr>
<td>Stomach</td>
<td>-1.7*</td>
</tr>
<tr>
<td>Corpus &amp; Uterus, NOS</td>
<td></td>
</tr>
<tr>
<td>Lung &amp; Bronchus (Male)</td>
<td></td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx</td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td></td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td></td>
</tr>
</tbody>
</table>

**Source:** SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

The APC is the Annual Percent Change over the time interval.

* The APC is significantly different from zero (p<.05).
**Trends in US Death Rates by Primary Cancer Site 1992-2002**

**Ages Less Than 65**

- Liver & IBD: -4.4*
- Corpus & Uterus, NOS: -4.2*
- Thyroid: -2.9*
- Pancreas: -2.9*
- Urinary Bladder: -2.7*
- Testis: -2.6*
- Esophagus: -2.6*
- Kidney & Renal Pelvis: -2.5*
- Ovary: -2.5*
- Brain & ONS: -2.5*
- Colon & Rectum: -2.4*
- All Except Lung: -2.4*
- Myeloma: -2.3*
- Melanoma of the Skin: -2.3*
- Lung & Bronchus (Female): -2.2*
- All Cancer Sites: -2.2*
- Leukemia: -2.2*
- Cervix Uteri: -2.2*
- Stomach: -2.1*
- Breast (Female): -2.1*
- Oral Cavity & Pharynx: -2.1*
- Larynx: -2.1*
- Non-Hodgkin Lymphoma: -2.1*
- Lung & Bronchus (Male): -2.1*
- Prostate: -2.0*
- Hodgkin Lymphoma: -1.9*

**Ages 65 and Over**

- Lung & Bronchus (Female): 1.7*
- Liver & IBD: 1.5*
- Esophagus: 1.5*
- Melanoma of the Skin: 0.9*
- Thyroid: 0.6*
- Kidney & Renal Pelvis: 0.4*
- Non-Hodgkin Lymphoma: 0.2*
- Leukemia: 0.2*
- Myeloma: 0.0*
- Ovary: 0.0*
- Pancreas: 0.0*
- Urinary Bladder: 0.0*
- Brain & ONS: 0.0*
- All Cancer Sites: 0.0*
- Corpus & Uterus, NOS: 0.0*
- All Except Lung: 0.0*
- Lung & Bronchus (Male): 1.3*
- Testis: 1.3*
- Larynx: 1.5*
- Hodgkin Lymphoma: 1.6*
- Breast (Female): 1.8*
- Colon & Rectum: 1.9*
- Oral Cavity & Pharynx: 2.0*
- Stomach: 2.1*
- Prostate: 2.1*
- Cervix Uteri: 2.1*

Source: NCHS public use data file for the total US.
Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
The APC is the Annual Percent Change over the time interval.
* The APC is significantly different from zero (p<.05).
Trends in SEER Incidence Rates by Primary Cancer Site 1992-2002

All Races, Males

- Thyroid: 3.1*  
- Liver & IBD: 3.0*  
- Melanoma of the Skin: 2.5*  
- Kidney & Renal Pelvis: 1.4*  
- Testis: 1.1*  
- Esophagus: 0.3  
- Hodgkin Lymphoma: -0.1  
- Urinary Bladder: -0.2  
- Pancreas: -0.4*  
- Non-Hodgkin Lymphoma: -0.5  
- Myeloma: -0.5  
- Brain & ONS: -0.7  
- Leukemia: -1.1*  
- All Except Lung: -1.2*  
- Colon & Rectum: -1.2*  
- All Cancer Sites: -1.3*  
- Oral Cavity & Pharynx: -1.8*  
- Prostate: -2.0*  
- Stomach: -2.1*  
- Lung & Bronchus: -2.2*  
- Larynx: -3.3*  

All Races, Females

- Thyroid: 4.8*  
- Liver & IBD: 3.3*  
- Melanoma of the Skin: 2.3*  
- Kidney & Renal Pelvis: 1.4*  
- Non-Hodgkin Lymphoma: 0.8*  
- Breast: 0.4  
- All Cancer Sites: 0.1  
- All Except Lung: 0.1  
- Lung & Bronchus: -0.2  
- Corpus & Uterus, NOS: -0.2  
- Pancreas: -0.3  
- Urinary Bladder: -0.4*  
- Brain & ONS: -0.5  
- Hodgkin Lymphoma: -0.5  
- Colon & Rectum: -0.6*  
- Stomach: -0.7  
- Myeloma: -0.8  
- Leukemia: -0.8*  
- Ovary: -0.9*  
- Esophagus: -1.0*  
- Oral Cavity & Pharynx: -1.1*  
- Larynx: -2.4*  
- Cervix Uteri: -2.8*  

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).  
Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).  
The APC is the Annual Percent Change over the time interval.  
* The APC is significantly different from zero (p<.05).
Source: NCHS public use data file for the total US. Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). The APC is the Annual Percent Change over the time interval. * The APC is significantly different from zero (p<.05).
Figure I-10

Trends in US Death Rates, 1992-2002 by Primary Cancer Site
All Ages, by Race

Source: NCHS public use data file for the total US.
The APC is the Annual Percent Change over the time interval.
Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Source: NCHS public use data file for the total US. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).